Lanreotide
FDA Approved: * December 17, 2021Pharm Company: * INVAGEN PHARMS
Category: Acromegaly
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for s... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.1 Discussion
Dosage List
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection
NDC: 76282-709
Labeler:
Exelan Pharmaceuticals, Inc.
Lanreotide Acetate 90 mg/.3ml Subcutaneous Injection
NDC: 76282-710
Labeler:
Exelan Pharmaceuticals, Inc.
Lanreotide Acetate 120 mg/.5ml Subcutaneous Injection
NDC: 76282-711
Labeler:
Exelan Pharmaceuticals, Inc.
Lanreotide Acetate 60 mg/.2ml Subcutaneous Injection
NDC: 76282-718
Labeler:
Exelan Pharmaceuticals, Inc.